BOSTON--(BUSINESS WIRE)--March 28, 2006--PerkinElmer, Inc. (NYSE: PKI), a global technology leader in Health Sciences and Photonics, announced today a five-year research collaboration agreement with George Mason University to develop a new and innovative approach for cancer detection and risk stratification. Scientists from both organizations will work together on the design of several new types of clinical assay platforms that utilize both the amino acid identification of a protein fragment and its specific mass to identify the biomarker. Areas of focused research include Stage I lung, ovarian and breast cancers.
